Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets

Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets Ahmedabad, 9 October, 2019 Zydus Cadila has received the final approval from the USFDA to market Colesevelam Hydrochloride Tablets, (US RLD - Welchol), 625 mg. This medication is used along with a proper diet and exercise, to lower cholesterol in people with high levels of cholesterol in the blood. Lowering cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. It will be manufact ured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The group now has 273 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗